At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 274 enrolled
Drug / intervention
Eslicarbazepine acetatedrug
Likely dose
Eslicarbazepine acetate 2400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long Term Eslicarbazepine Acetate Extension Study
In Brief
A Phase 3 clinical trial evaluating Eslicarbazepine acetate for Epilepsy. Completed, enrolled 274 participants across 122 sites in 6 countries.
Detailed Summary
This is a long term, open-label, safety extension study in subjects with partial onset seizures.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesBulgaria, Canada, Czechia, Serbia, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartAug 2009
Primary CompletionApr 2017
TodayJul 2026
First PostedMay 29, 2009
Enrollment StartAug 1, 2009
Primary CompletionApr 15, 2017
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 17.1 years ago
Interventions
Eslicarbazepine acetatedrug
800 to 2400 mg once daily (QD)